111 related articles for article (PubMed ID: 8471342)
1. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
Verweij J; Gandia D; Planting AS; Stoter G; Armand JP
Eur J Cancer; 1993; 29A(5):778-9. PubMed ID: 8471342
[No Abstract] [Full Text] [Related]
2. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Verweij J; Planting A; van der Burg M; Stoter G
J Cancer Res Clin Oncol; 1992; 118(8):606-8. PubMed ID: 1325463
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cystemustine in advanced head and neck cancer. A trial of the EORTC Clinical Screening Group.
Cappelaere P; Lentz MA; Degardin M; Chauvergne J; Mayer F; Chollet P; Chevallier B
Eur J Cancer B Oral Oncol; 1995 Mar; 31B(2):151-2. PubMed ID: 7633288
[No Abstract] [Full Text] [Related]
4. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Degardin M; Cappelaere P; Krakowski I; Fargeot P; Cupissol D; Brienza S
Eur J Cancer B Oral Oncol; 1996 Jul; 32B(4):278-9. PubMed ID: 8776427
[No Abstract] [Full Text] [Related]
5. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
[No Abstract] [Full Text] [Related]
6. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
[No Abstract] [Full Text] [Related]
7. Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung.
Cappelaere P; Guiochet N; Bastit P; Favre R; Vanderburg M; Goupil A; Chauvergne J; Thomas D; Van Glabbeke M; Armand JP
Eur J Cancer; 1993; 29A(8):1216. PubMed ID: 8518037
[No Abstract] [Full Text] [Related]
8. Phase II evaluation of diaziquone in recurrent head and neck cancer.
Kish JA; Ensley J; Al-Sarraf M
Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
[No Abstract] [Full Text] [Related]
9. Oral preneoplasia and chemoprevention of squamous cell carcinoma of the head and neck.
Kucuk O
Cancer Treat Res; 2003; 114():61-83. PubMed ID: 12619538
[No Abstract] [Full Text] [Related]
10. Phase II trial of thioproline in advanced epidermoid head and neck tumors.
Boccardo F; Barbieri A; Canobbio L; Guarneri D; Merlano M; Rosso R
Cancer Treat Rep; 1982 Mar; 66(3):585-6. PubMed ID: 7060048
[No Abstract] [Full Text] [Related]
11. Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer.
Krasnow S; Green M; Perry DJ; Eisenberger MA; Johnston-Early A; Muggia F; Cohen MH
Cancer Treat Rep; 1986 Aug; 70(8):1039-40. PubMed ID: 3524834
[No Abstract] [Full Text] [Related]
12. [Development on squamous-cell cancer of the head and neck].
García Sáenz JA; Bueno Muiño C
An Med Interna; 2008 Apr; 25(4):157-8. PubMed ID: 18604329
[No Abstract] [Full Text] [Related]
13. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Gebbia V; Testa A; Valenza R; Zerillo G; Restivo S; Ingria F; Cannata G; Gebbia N
Eur J Cancer; 1993; 29A(9):1358-9. PubMed ID: 8343289
[No Abstract] [Full Text] [Related]
14. Integration of chemotherapy into the definitive management of squamous cell head and neck cancer.
Adelstein DJ
Curr Oncol Rep; 1999; 1(2):97-8. PubMed ID: 11122804
[No Abstract] [Full Text] [Related]
15. Evaluation of gallium nitrate in metastatic or locally recurrent squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Decker DA; Costanzi JJ; McCracken JD; Baker LH
Cancer Treat Rep; 1984; 68(7-8):1047-8. PubMed ID: 6744339
[No Abstract] [Full Text] [Related]
16. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy in squamous cell carcinoma of the head and neck: saved by the bell?
Specenier P
Oral Oncol; 2015 Feb; 51(2):e5-7. PubMed ID: 25497106
[No Abstract] [Full Text] [Related]
18. Chemotherapy in head and neck cancer: an unfulfilled promise and a continued challenge.
Shah JP
J Surg Oncol; 1994 Feb; 55(2):69-70. PubMed ID: 8121187
[No Abstract] [Full Text] [Related]
19. Chemotherapy of head and neck cancer.
Alberts DS; Coulthard SW
Ariz Med; 1977 Oct; 34(10):695-7. PubMed ID: 931664
[No Abstract] [Full Text] [Related]
20. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Patel V; Lahusen T; Sy T; Sausville EA; Gutkind JS; Senderowicz AM
Cancer Res; 2002 Mar; 62(5):1401-9. PubMed ID: 11888912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
